Lanean...
Pathogen Acquisition in Patients with Cystic Fibrosis Receiving Ivacaftor or Lumacaftor/Ivacaftor
BACKGROUND: The CFTR modulators ivacaftor and lumacaftor/ivacaftor improve the status of existing infections in patients with cystic fibrosis (CF). It is unknown how well these drugs protect patients against incident infections. We hypothesized that CFTR modulator treatment would decrease new infect...
Gorde:
| Argitaratua izan da: | Pediatr Pulmonol |
|---|---|
| Egile Nagusiak: | , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6641998/ https://ncbi.nlm.nih.gov/pubmed/31012285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.24341 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|